Abstract
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Current Vascular Pharmacology
Title:Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Volume: 10 Issue: 6
Author(s): Marcello Arca, Giovanni Pigna and Carla Favoccia
Affiliation:
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Abstract: Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Export Options
About this article
Cite this article as:
Arca Marcello, Pigna Giovanni and Favoccia Carla, Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520864
DOI https://dx.doi.org/10.2174/157016112803520864 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design Human Imprinting Anomalies in Fetal and Childhood Growth Disorders: Clinical Implications and Molecular Mechanisms
Current Pharmaceutical Design Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Intramolecular Cyclisation of β-Aryl-β-Amino Acids in the Design of Novel Heterocyclic Systems with Therapeutic Interest: An Unfailing Source of Diversity
Current Medicinal Chemistry Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Peptide Inhibitors of a-Amylase Based on Tendamistat: Development of Analogues with ϖ-Amino Acids Linking Critical Binding Segments
Protein & Peptide Letters Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes
Current Drug Discovery Technologies Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets A Molecular Approach on the Protective Effects of Mangiferin Against Diabetes and Diabetes-related Complications
Current Diabetes Reviews The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Treating Diabetes Mellitus in Older and Oldest Old Patients
Current Pharmaceutical Design Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice
Current Vascular Pharmacology Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets Bone Diseases Associated with Human Immunodeficiency Virus Infection: Pathogenesis, Risk Factors and Clinical Management
Current Molecular Medicine Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Nutrition Transition and Obesity Among Teenagers and Young Adults in South Asia
Current Diabetes Reviews Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology